论文部分内容阅读
目的:探讨盐酸氨溴索静脉滴注治疗急性脑卒中相关性肺炎的价值。方法:将来我院就诊的66例急性脑卒中相关性肺炎患者作为调查对象,通过抽样法将其分为治疗组33例与对照组33例,对比两组患者治疗后的临床疗效、不良反应发生率、住院时间、退热时间、动脉血氧分压、C反应蛋白等。结果:治疗组的总有疗效为93.87%,与对照组的78.54%相比,疗效较为显著,其中治疗组不良反应发生率、住院时间、退热时间明显要比对照组显著,两组患者的比较差异显著,P<0.05,具有一定的统计学意义。结论:对急性脑卒中相关性肺炎患者实施盐酸氨溴索静脉滴注治疗,可有效降低不良反应发生率,提高临床疗效,值得推广使用。
Objective: To investigate the value of intravenous ambroxol hydrochloride in the treatment of acute stroke-associated pneumonia. Methods: In the future, 66 cases of acute stroke-associated pneumonia in our hospital were investigated. The patients were divided into treatment group (33 cases) and control group (33 cases) by sampling method. The clinical efficacy and adverse reactions of two groups were compared Rate, hospital stay, antipyretic time, arterial oxygen pressure, C-reactive protein and so on. Results: The total effective rate in the treatment group was 93.87%, which was significantly higher than that in the control group (78.54%). The incidence of adverse reactions, hospitalization time and antipyretic time in the treatment group were significantly higher than those in the control group The difference was significant, P <0.05, with a certain statistical significance. Conclusion: The administration of ambroxol hydrochloride intravenous infusion in patients with acute stroke-associated pneumonia can effectively reduce the incidence of adverse reactions and improve clinical efficacy, which is worth promoting.